Maria Boustani, MD
Pulmonary Disease · Beckley, WVNPI 1518917632
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $86,207 of the $95,386 with a category attached, or 90.4%. GSK accounts for 66.0% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $19,508 and has fallen 88.4% since, to $2,262 in 2025. Among pulmonary disease clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $298.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$63K
- Boehringer Ingelheim$15K
- Sunovion Pharmaceuticals Inc.$6K
- Sanofi$5K
- Regeneron Healthcare Solutions, Inc.$3K
- UCB, Inc.$718
- plus $3K from 29 others
Across 75 payments — averaging $7567.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$565K
- Boehringer Ingelheim International GmbH$2K
What the payments were for
- Consulting fees$2,4483%
- Speaking & faculty fees$86,20790%
- Travel & lodging$1,5092%
- Food & beverage$5,1285%
- Education$940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 74 | $62,992 |
| Boehringer Ingelheim | 27 | $15,348 |
| Sunovion Pharmaceuticals Inc. | 18 | $6,389 |
| Sanofi | 21 | $4,654 |
| Regeneron Healthcare Solutions, Inc. | 17 | $2,700 |
| UCB, Inc. | 61 | $718 |
| Novartis | 17 | $315 |
| Merck | 5 | $250 |
| Johnson & Johnson | 14 | $238 |
| Amgen | 9 | $185 |
| Mallinckrodt Hospital Products Inc. | 4 | $174 |
| ANI Pharmaceuticals, Inc. | 6 | $164 |
| Regeneron | 3 | $161 |
| AstraZeneca(2 entities) | 5 | $154 |
| United Therapeutics Corporation | 1 | $119 |
| Baxter Healthcare | 7 | $118 |
| Radius Health, Inc. | 4 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $94 |
| Bristol Myers Squibb | 2 | $88 |
| Sandoz | 4 | $60 |
| Shire North American Group Inc | 1 | $51 |
| Genentech USA, Inc. | 1 | $40 |
| Aurinia Pharma U.S., Inc. | 2 | $37 |
| Verona Pharma, Inc. | 1 | $32 |
| Organon | 2 | $31 |
| Mylan Specialty L.p. | 2 | $27 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $19 |
| Apria Healthcare LLC | 1 | $18 |
| Insmed, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Lilly USA, LLC | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $12 |
| Bioventus LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$41,350
- DUPIXENT$6,550
- LONHALA MAGNAIR$5,990
- OFEV$128
- TYVASO$119
How this compares
$95,386 in reported general payments places this provider in the 95th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GlassiaAlpha-1-Proteinase Inhibitor | 107 | $1,334,790 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 430 | $376,479 |
| OfevNintedanib Esylate | 20 | $261,657 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 18 | $177,130 |
| ZemairaAlpha-1-Proteinase Inhibitor | 18 | $152,642 |
| Breo ElliptaFluticasone/Vilanterol | 181 | $88,296 |
| Dupixent PenDupilumab | 22 | $85,001 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 109 | $82,703 |
| XolairOmalizumab | 26 | $81,101 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 127 | $71,738 |
| Fasenra PenBenralizumab | 11 | $62,658 |
| Dupixent SyringeDupilumab | 16 | $60,851 |
| TezspireTezepelumab-Ekko | 11 | $47,864 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $36,198 |
| Spiriva HandihalerTiotropium Bromide | 47 | $29,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $94 | $1,334,790107 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $62,992 | $528,303755 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $15,348 | $357,542192 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $154 | $144,216169 claims |
| MerckDulera | $250 | $18,36734 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Beckley
- Ramzi HaddadinBeckley$43K
- Charles PorterfieldBeckley$8K
- Shirkant BembalkarBeckley$746
- William PowersBeckley$589
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Salam RajjoubBridgeport$29K
- Peter KochupuraMorgantown$22K
- Phillip AguilaMartinsburg$21K
- Ryan WaddellCharleston$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.